Island to present at World Antiviral Congress 2022
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, DrDavid Foster will present at the World Antiviral Congress 2022 inSan Diego, USA which ...
Island Pharmaceuticals to discuss its potential dengue fever preventative at Pharma Meeting Brazil & Latam 2021
MELBOURNE, Australia, Oct. 20, 2021 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to be attending Pharma Meeting Brazil & Latam 2021, this week and presenting to potential partners. Island's attendance at the co...
Island Pharmaceuticals granted key patent for ISLA-101 in the United States
* Island's lead asset, ISLA-101 granted key patent from United Stated Patent & Trademark Office * Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever. * Around 3...
Island Pharmaceuticals Limited to list on the ASX today following oversubscribed A$7.5m IPO
MELBOURNE, Australia, April 13, 2021 /PRNewswire/ -- Australian antiviral drug development company, Island Pharmaceuticals (Island) is set to list on the Australian Securities Exchange (ASX) today after raisingA$7.5 million through its Initial Public Offer (IPO) which was significantly oversubscr...
